Details
Role
Team Leader / Senior Research Officer
Research area
Genomic Medicine
Group
Muscle Research
Dr Peter Houweling is a Team leader and senior research officer in the Muscle Research group at the Murdoch Children’s Research Institute (MCRI). He completed his PhD at the University of Sydney and post-doctoral appointments at the Children’s Hospital Westmead, before moving the MCRI in 2013.
He has almost 15 years of experience in the laboratory where he is working to understand the impact of genetic variants on skeletal muscle performance in health and disease.
His Team now focuses on using stem cells to model and test new treatments for patients with genetic muscle diseases, including Duchenne muscular dystrophy (DMD), Facioscapulohumeral muscular dystrophy (FSHD) and other congenital muscular dystrophies.
He has almost 15 years of experience in the laboratory where he is working to understand the impact of genetic variants on skeletal muscle performance in health and disease.
His Team now focuses on using stem cells to model and test new treatments for patients with genetic muscle diseases, including Duchenne muscular dystrophy (DMD), Facioscapulohumeral muscular dystrophy (FSHD) and other congenital muscular dystrophies.
Dr Peter Houweling is a Team leader and senior research officer in the Muscle Research group at the Murdoch Children’s Research Institute (MCRI). He completed his PhD at the University of Sydney and post-doctoral appointments at the Children’s...
Dr Peter Houweling is a Team leader and senior research officer in the Muscle Research group at the Murdoch Children’s Research Institute (MCRI). He completed his PhD at the University of Sydney and post-doctoral appointments at the Children’s Hospital Westmead, before moving the MCRI in 2013.
He has almost 15 years of experience in the laboratory where he is working to understand the impact of genetic variants on skeletal muscle performance in health and disease.
His Team now focuses on using stem cells to model and test new treatments for patients with genetic muscle diseases, including Duchenne muscular dystrophy (DMD), Facioscapulohumeral muscular dystrophy (FSHD) and other congenital muscular dystrophies.
He has almost 15 years of experience in the laboratory where he is working to understand the impact of genetic variants on skeletal muscle performance in health and disease.
His Team now focuses on using stem cells to model and test new treatments for patients with genetic muscle diseases, including Duchenne muscular dystrophy (DMD), Facioscapulohumeral muscular dystrophy (FSHD) and other congenital muscular dystrophies.